Latest News in the pharma Industry

Research & Development

New Tool Identifies Novel Compound Targeting Causes of Type 2 Diabetes

New Tool Identifies Novel Compound Targeting Causes of Type 2 Diabetes

18 Jun 2015

Read more 
New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use

New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use

18 Jun 2015

Read more 
Novartis Presents New Data from Large European Study Reinforcing the Benefit of First-Line Tasigna in Newly-Diagnosed Patients with CML

Novartis Presents New Data from Large European Study Reinforcing the Benefit of First-Line Tasigna in Newly-Diagnosed Patients with CML

17 Jun 2015

Read more 
Eli Lilly Enters Into Strategic Partnership with Sarah Cannon Research Institute to Develop Investigational Oncology Therapy

Eli Lilly Enters Into Strategic Partnership with Sarah Cannon Research Institute to Develop Investigational Oncology Therapy

17 Jun 2015

Read more 
Novartis Drug Arzerra Improved Median Progression-Free Survival by 54% in Patients with Relapsed Chronic Lymphocytic Leukemia

Novartis Drug Arzerra Improved Median Progression-Free Survival by 54% in Patients with Relapsed Chronic Lymphocytic Leukemia

15 Jun 2015

Read more 
Bial to Present Data on Opicapone at the 19th International Congress of Parkinson's Disease and Movement Disorders

Bial to Present Data on Opicapone at the 19th International Congress of Parkinson's Disease and Movement Disorders

12 Jun 2015

Read more 
Pfizer Reports Top Line Results from a Phase III Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation

Pfizer Reports Top Line Results from a Phase III Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation

12 Jun 2015

Read more 
BMS Demonstrates Commitment to Hematology and Advancing R&D Across Multiple Blood Cancers Through Immuno-Oncology Leadership

BMS Demonstrates Commitment to Hematology and Advancing R&D Across Multiple Blood Cancers Through Immuno-Oncology Leadership

11 Jun 2015

Read more 
LDC to Collaborate with Johnson & Johnson Innovation on Acceleration of Academic Drug Discovery Initiatives

LDC to Collaborate with Johnson & Johnson Innovation on Acceleration of Academic Drug Discovery Initiatives

11 Jun 2015

Read more 
TECOS, Merck’s Cardiovascular Safety Trial of Januvia (Sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes

TECOS, Merck’s Cardiovascular Safety Trial of Januvia (Sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes

9 Jun 2015

Read more 
Lilly's Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes

Lilly's Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes

8 Jun 2015

Read more 
Celgene and bluebird bio to Develop Anti-BCMA Product Candidates

Celgene and bluebird bio to Develop Anti-BCMA Product Candidates

5 Jun 2015

Read more